Lack of effect of desmopressin on ACTH and cortisol responses to ovine corticotropin‐releasing hormone in anorexia nervosa
- 1 October 1996
- journal article
- clinical trial
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 26 (10) , 879-883
- https://doi.org/10.1111/j.1365-2362.1996.tb02133.x
Abstract
Both arginine vasopressin (AVP) and corticotropin‐releasing hormone (CRH) are involved in the release of ACTH in man. Desmopressin (DDAVP), a synthetic analogue of AVP, has been shown to have a CRH‐like action (able to promote ACTH and cortisol release) in animals but not in normal man. Nevertheless, DDAVP is able to release ACTH and cortisol in ACTH‐dependent Cushing's disease. We studied eight anorexia nervosa (AN) patients [as AN is a condition in which chronic activation of the hypothalamic‐pituitary‐adrenal (HPA) axis is commonly reported] in a refeeding phase of the disease, to evaluate whether, after weight gain, ACTH and cortisol response to ovine corticotropin‐releasing hormone (oCRH) [1 μg kg‐1 body weight (BW) i.v.] is restored. We also wanted to ascertain the effect on the HPA axis of 10 μg i.v. DDAVP alone and as pretreatment to oCRH (1 μg kg‐1 BW i.v.)‐induced secretion of ACTH and cortisol. We studied six normal women as control subjects. No significant differences in ACTH and cortisol responses to oCRH were found between AN patients and control subjects. DDAVP was not able to stimulate ACTH or cortisol release in AN patients or in control subjects, but in the latter it was able to significantly enhance (P < 0.05) ACTH [area under curve (AUC): 590.0± 104.4 pmol L‐1 120 min‐1 and cortisol (AUC: 28899.0 ± 6935.2nmol L‐1 120 min‐1) responses to oCRH (ACTH AUC: 325.7 ± 101.7 pmol L‐1 120 min‐1, cortisol AUC: 14197.4 ± 2930.0 nmol L‐1 120 min‐1). The present data show that DDAVP does not stimulate ACTH and cortisol in AN patients or, as previously reported, in normal subjects. However, DDAVP is able to enhance ACTH and cortisol release after oCRH administration in normal subjects but not in AN patients. This finding could be due to a down‐regulation of hypophyseal DDAVP V3 receptors in AN as a direct consequence of the hypercortisolaemic status usually present.Keywords
This publication has 26 references indexed in Scilit:
- Cloning and characterization of the human V3 pituitary vasopressin receptorFEBS Letters, 1994
- The desmopressin stimulation test in the differential diagnosis of Cushing's syndromeClinical Endocrinology, 1993
- Psychoimmunoendocrine Investigation in Anorexia nervosaNeuropsychobiology, 1993
- Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.Journal of Clinical Investigation, 1988
- Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressinLife Sciences, 1988
- Hormonal effects of CV 205–502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist propertiesLife Sciences, 1988
- Abnormal Hypothalamic–Pituitary–Adrenal Function in Anorexia NervosaNew England Journal of Medicine, 1986
- MANAGEMENT OF CRANIAL DIABETES INSIPIDUS WITH ORAL DESMOPRESSIN (DDAVP)Clinical Endocrinology, 1986
- HORMONAL AND CARDIOVASCULAR RESPONSES TO DDAVP IN MANClinical Endocrinology, 1986
- Relationship between weight gain and hypothalamic pituitary adrenal function in patients with anorexia nervosaThe Journal of Steroid Biochemistry and Molecular Biology, 1980